Many of us will remember the excitement a couple of years back when Dr Carl June of the University of Pennsylvania announced Chimeric Antigen Receptor engineered T Lymphocytes (CAR-T) were successfully used to cure at least one CLL patient.
As Dr Sharman covers in his latest blog, CAR-T research is now being done at a multitude of universities, with one for relapsed DLBCL or multiply recurrent indolent lymphoma being run out of the NIH:
When the CAR-T research was publicised, it was recognised that much more needed to done to provide a more broadly useful treatment, rather than a custom approach per patient. (The trial patients needed to remain on IVIG for life as the treatment kept zapping any new B-Lymphocytes). It's great to know that so many centres are working on extending this alternative approach to finding a cure for some tough leukaemias and lymphomas.
Dr Sharman concludes: "If I had relapsed DLBCL or multiply recurrent indolent lymphoma, I would be on the first plane to NIH for these studies."
(My accompanying picture shows the aptly named 'bottle brush', an attractive native shrub that is sometimes used as a street tree around here. They've been glorious this year after a wet winter.)